Puma's share price has dropped by 23% since January despite healthy financials and competitive market multiples at the time. A look at the company's earnings since indicates why. Operating profit has ...

Wondering whether PUMA is a beaten down bargain or a value trap at current levels? This breakdown will help you decide without getting lost in hype or headlines. The stock has bounced about 3.1% over ...

Puma shares slumped on Thursday as the German apparel maker's preliminary fourth-quarter numbers disappointed analysts. Puma reported fourth-quarter revenue growth, at constant currencies, of 9.8% to ...

Trump 2.0 A Sneaker Head's Nightmare? Your Next Pair Of Nikes Or Vans Could Cost A Pretty Penny: Here's Why A wave of concern is sweeping through the athletic footwear industry as Donald Trump's ...

In a surprising turn of events, Puma's shares surged over 22% on August 25, despite a year of poor performance and economic headwinds. However, there's a reason behind this unexpected change in the ...

Shares of Puma tumbled to a near nine-year low on Wednesday after the German sportswear group warned that geopolitical tensions and trade uncertainty would contribute to another year of weak growth.

Puma faces significant headwinds: Weak US/China demand, leadership turnover, and a 41% stock drop since my last article. Despite challenges, I see potential for a long-term turnaround, especially with ...

One stock that might be an intriguing choice for investors right now is Puma Biotechnology, Inc. PBYI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...

A securities class action alleging wrongdoing by Puma Biotechnology Inc. is headed for trial early next year after a judge postponed proceedings, originally scheduled for Nov. 6. The suit seeks more ...

Puma Biotechnology offices in Westwood. After a year of lackluster and disappointing performance, shares of Westwood-based biopharmaceutical company Puma Biotechnology Inc. mysteriously shot up 81% ...

For shareholders of Puma SE, 2025 has been a year to forget, with recent reports of a possible takeover providing only the thinnest of silver linings. While the stock bounced off its lows last week, ...

Puma's window of opportunity to build a bigger pipeline around neratinib just got a little smaller. So what: For years, Puma Biotechnology has circled its wagons -- a lot of wagons -- around neratinib ...